Welcome to our dedicated page for Day One Biopharmaceuticals news (Ticker: DAWN), a resource for investors and traders seeking the latest updates and insights on Day One Biopharmaceuticals stock.
Day One Biopharmaceuticals was a Nasdaq-listed biopharmaceutical company focused on targeted therapies for people of all ages with life-threatening diseases. News about DAWN centered on oncology product and pipeline developments, including OJEMDA (tovorafenib), an FDA-approved medicine marketed in the U.S. for pediatric low-grade glioma, and clinical-stage assets in rare cancers.
Coverage also includes the completed acquisition by Servier, related shareholder-rights and governance notices, capital-structure updates, operating and financial results, and clinical or regulatory disclosures tied to OJEMDA and other oncology programs.
Day One Biopharmaceuticals (Nasdaq: DAWN) has received Rare Pediatric Disease Designation from the FDA for its lead product DAY101, aimed at treating low-grade gliomas in children with RAF alterations. This designation highlights the urgent need for effective therapies for pediatric low-grade gliomas (pLGG), which currently have no approved treatments. DAY101 is a type II pan-RAF inhibitor and is now part of the pivotal Phase 2 FIREFLY-1 clinical trial. If DAY101 is approved, Day One may receive a Priority Review Voucher from the FDA.
Day One Biopharmaceuticals announced that the European Commission granted orphan designation for its lead product candidate, DAY101, to treat glioma. This decision follows a positive opinion from the European Medicines Agency. DAY101, an oral pan-RAF kinase inhibitor, is under pivotal Phase 2 trial (FIREFLY-1) for pediatric patients with low-grade glioma exhibiting known BRAF alterations. The orphan designation provides benefits like reduced regulatory fees and potential market exclusivity. Currently, there are no approved therapies for pediatric low-grade glioma.
Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN) has successfully closed its initial public offering (IPO) of 11.5 million shares at $16.00 per share, raising gross proceeds of $184 million. This includes the full exercise of underwriters' options for an additional 1.5 million shares. The IPO shares began trading on May 27, 2021. Day One is focused on developing targeted therapies for patients with genetically defined cancers, particularly children. Its lead candidate, DAY101, is in a pivotal Phase 2 trial for treating relapsed or progressive low-grade gliomas.
Day One Biopharmaceuticals (Nasdaq: DAWN) has priced its initial public offering (IPO) at $16.00 per share, offering 10,000,000 shares. The expected gross proceeds are $160 million, before deductions. Trading begins on Nasdaq on May 27, 2021, with closing anticipated by June 1, 2021, pending customary conditions. Underwriters, including J.P. Morgan and Cowen, have a 30-day option for an additional 1,500,000 shares. The company focuses on targeted therapies for genetically defined cancers, particularly in pediatric patients.